Full Text
PRICE NEGOTIATIONS IN CONTEXT OF EARLY BENEFIT ASSESSMENT IN GERMANY- IS A FLAT PRICING MODEL FOR NEW DRUGS ENFORCEABLE?

Abstract

Authors

D. Bot D. Schneider T. Ecker

Back to Volume 19, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×